Ozanimod (Zeposia®). HTA ID: 20045

Assessment Status Rapid Review Complete
HTA ID 20045
Drug Ozanimod
Brand Zeposia®
Indication For the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.
Assessment Process
Rapid review commissioned 06/10/2022
Rapid review completed 23/11/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ozanimod compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations August 2021